Earnings results for CNS Pharmaceuticals (NASDAQ:CNSP)
CNS Pharmaceuticals, Inc. is estimated to report earnings on 11/23/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.
Analyst Opinion on CNS Pharmaceuticals (NASDAQ:CNSP)
2 Wall Street analysts have issued ratings and price targets for CNS Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.00, predicting that the stock has a possible upside of 388.89%. The high price target for CNSP is $11.00 and the low price target for CNSP is $11.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
There is not enough analysis data for CNS Pharmaceuticals.
Dividend Strength: CNS Pharmaceuticals (NASDAQ:CNSP)
CNS Pharmaceuticals does not currently pay a dividend. CNS Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: CNS Pharmaceuticals (NASDAQ:CNSP)
In the past three months, CNS Pharmaceuticals insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $289,680.00 in company stock and sold $0.00 in company stock. Only 8.70% of the stock of CNS Pharmaceuticals is held by insiders. Only 0.56% of the stock of CNS Pharmaceuticals is held by institutions.
Earnings and Valuation of CNS Pharmaceuticals (NASDAQ:CNSP
Earnings for CNS Pharmaceuticals are expected to decrease in the coming year, from ($0.50) to ($0.53) per share. The P/E ratio of CNS Pharmaceuticals is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of CNS Pharmaceuticals is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. CNS Pharmaceuticals has a P/B Ratio of 15.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here